HomeCompareNHBAF vs ABBV

NHBAF vs ABBV: Dividend Comparison 2026

NHBAF yields 2.17% · ABBV yields 3.09%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ABBV wins by $81.9K in total portfolio value
10 years
NHBAF
NHBAF
● Live price
2.17%
Share price
$12.70
Annual div
$0.28
5Y div CAGR
-7.9%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$21.8K
Annual income
$105.18
Full NHBAF calculator →
ABBV
AbbVie Inc.
● Live price
3.09%
Share price
$214.96
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$103.7K
Annual income
$25,324.79
Full ABBV calculator →

Portfolio growth — NHBAF vs ABBV

📍 ABBV pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodNHBAFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, NHBAF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
NHBAF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

NHBAF
Annual income on $10K today (after 15% tax)
$184.46/yr
After 10yr DRIP, annual income (after tax)
$89.40/yr
ABBV
Annual income on $10K today (after 15% tax)
$262.96/yr
After 10yr DRIP, annual income (after tax)
$21,526.07/yr
At 15% tax rate, ABBV beats the other by $21,436.67/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of NHBAF + ABBV for your $10,000?

NHBAF: 50%ABBV: 50%
100% ABBV50/50100% NHBAF
Portfolio after 10yr
$62.8K
Annual income
$12,714.98/yr
Blended yield
20.26%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

NHBAF
No analyst data
Altman Z
2.9
Piotroski
5/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+19.2% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

NHBAF buys
0
ABBV buys
0
No recent congressional trades found for NHBAF or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricNHBAFABBV
Forward yield2.17%3.09%
Annual dividend / share$0.28$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-7.9%40.6%
Portfolio after 10y$21.8K$103.7K
Annual income after 10y$105.18$25,324.79
Total dividends collected$1.5K$62.2K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: NHBAF vs ABBV ($10,000, DRIP)

YearNHBAF PortfolioNHBAF Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$10,900$199.86$11,555$434.96$655.00ABBV
2$11,850$187.51$13,485$635.47$1.6KABBV
3$12,855$175.48$15,933$937.67$3.1KABBV
4$13,919$163.85$19,118$1,400.80$5.2KABBV
5$15,046$152.70$23,384$2,125.24$8.3KABBV
6$16,241$142.08$29,290$3,286.81$13.0KABBV
7$17,510$132.01$37,776$5,205.38$20.3KABBV
8$18,859$122.51$50,495$8,488.44$31.6KABBV
9$20,292$113.57$70,497$14,346.44$50.2KABBV
10$21,818$105.18$103,718$25,324.79$81.9KABBV

NHBAF vs ABBV: Complete Analysis 2026

NHBAFStock

Nichiban Co., Ltd. manufactures and sells medical products and tapes in Asia and Europe. It offers medical products, including surgical tapes, dressing tapes, first-aid bandages, hemostatic bandages, and others. The company also provides OTC products, such as anti-inflammatory patches, foot care products, waterproof films, and bandages. In addition, it offers taping tapes comprising cotton, elastic, kinesiology, strapping tapes, and others; and stationery products consisting of cellulose adhesive tapes, double sided tapes, adhesive transfer tapes, book binding tapes, and others. Further, the company provides industrial tapes for non-heavy duty packaging, carton boxes, agricultural use, vehicles, and machinery, as well as specialized tapes; and cellulose, OPP packing, kraft paper, lithographic, and crepe tapes. Nichiban Co., Ltd. was founded in 1918 and is headquartered in Tokyo, Japan.

Full NHBAF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this NHBAF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

NHBAF vs SCHDNHBAF vs JEPINHBAF vs ONHBAF vs KONHBAF vs MAINNHBAF vs JNJNHBAF vs MRKNHBAF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.